23/18. Tafenoquine- (KRINTAFEL)- (July 2018)- for the radical cure of Plasmodium vivax malaria
Drug Name:
23/18. Tafenoquine- (KRINTAFEL)- (July 2018)- for the radical cure of Plasmodium vivax malaria
List Of Brands:
Indication Type Description:
Indication:
BRIEF SUMMARY
TAFENOQUINE- (July 2018)
Indn- For the radical cure (prevention of relapse) of Plasmodium vivax malaria
Comp-
ADR-
CI-
Pat Inform-
=================================================================
U.S. FDA APPROVED DRUGS DURING 2018
Sr.No- 23
Name of the Drug- KRINTAFEL
Active Ingredient - Tafenoquine
Pharmacological Classification-
For the radical cure (prevention of relapse) of Plasmodium vivax malaria
Date of Approval- July 2018